Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Allergan | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Allergan

Specialized Therapeutics revenues up 7% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan
2Q Revenues: $4.1 billion (+3%)
2Q Earnings: $2.0 billion (+5%)
FY Revenues: $7.8 billion (+3%)
FY Earnings: $3.7 billion (+7%)
Comments: U.S. Specialized Therapeutics revenues grew 7% in the quarter to $1.8 billion, driven primarily by growth in Medical Aesthetics, including BOTOX Cosmetic, ALLODERM and the addition of CoolSculpting, as well as growth in BOTOX Therapeutic. In Neurosciences & Urology, BOTOX Therapeutic revenues were $404.7 million, up 17%. In Eye Care RESTASIS revenues were $318.2 million, down of 5%. ALPHAGAN/COMBIGAN  revenues were $98.1 million, up 2%. OZURDEX sales were up 11% to $27.6 million. U.S. General Medicine revenues were $1.3 billion, down 8%, impacted by lower revenues from NAMENDA XR  and ESTRACE due to generic competition, offset by growth from VRAYLAR, LINZESS, Lo LOESTRIN and anti-infectives including AVYCAZ.
VRAYLAR sales  grew 72% to $114.2 million. NAMENDA XR sales were $3.4 million, versus $118.7 million in 2Q17, impacted by loss of patent exclusivity in February 2018. LINZESS sales were $191.8 million, up 14% percent. Lo LOESTRIN sales were $127.8 million, up 13%. BYSTOLIC/BYVALSON sales were $148.1 million, down 2%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters